MSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities LawsPRNewsWire • 06/22/23
MRSN INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.PRNewsWire • 06/21/23
Mersana Therapeutics shares tank as FDA puts ovarian cancer drug trials on partial holdProactive Investors • 06/15/23
Mersana Therapeutics stock craters after FDA halts trials of ovarian cancer treatment after bleeding eventsMarket Watch • 06/15/23
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical TrialsGlobeNewsWire • 06/15/23
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/09/23
Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial ResultsGlobeNewsWire • 05/09/23
Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare ConferenceGlobeNewsWire • 05/03/23
Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023GlobeNewsWire • 05/02/23
Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual MeetingGlobeNewsWire • 04/26/23
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical TrialGlobeNewsWire • 03/13/23
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 02/28/23
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023GlobeNewsWire • 02/21/23
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing TumorsGlobeNewsWire • 01/25/23
Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected MilestonesGlobeNewsWire • 01/06/23
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug ConjugatesGlobeNewsWire • 12/22/22
European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian CancerGlobeNewsWire • 12/14/22